litlas
ログインアカウント作成

Michael S. Gordon

1980–2025 年に発表

126
論文数
25,669
被引用数
78
h 指数
122
i10 指数

被引用数

Michael S. Gordon の年別被引用数1984 年: 被引用 1 件1990 年: 被引用 2 件1991 年: 被引用 7 件1992 年: 被引用 28 件1993 年: 被引用 23 件1994 年: 被引用 17 件1995 年: 被引用 17 件1996 年: 被引用 24 件1997 年: 被引用 32 件1998 年: 被引用 39 件1999 年: 被引用 54 件2000 年: 被引用 62 件2001 年: 被引用 37 件2002 年: 被引用 58 件2003 年: 被引用 85 件2004 年: 被引用 85 件2005 年: 被引用 87 件2006 年: 被引用 90 件2007 年: 被引用 108 件2008 年: 被引用 118 件2009 年: 被引用 120 件2010 年: 被引用 111 件2011 年: 被引用 131 件2012 年: 被引用 144 件2013 年: 被引用 204 件2014 年: 被引用 219 件2015 年: 被引用 345 件2016 年: 被引用 419 件2017 年: 被引用 425 件2018 年: 被引用 441 件2019 年: 被引用 1,020 件2020 年: 被引用 1,142 件2021 年: 被引用 1,072 件2022 年: 被引用 881 件2023 年: 被引用 621 件2024 年: 被引用 798 件2025 年: 被引用 392 件2026 年: 被引用 9 件1985〜1989 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,148 件、この内訳の 29.5%中国: 引用元論文 1,660 件、この内訳の 11.8%イタリア: 引用元論文 736 件、この内訳の 5.2%イギリス: 引用元論文 729 件、この内訳の 5.2%フランス: 引用元論文 713 件、この内訳の 5.1%ドイツ: 引用元論文 653 件、この内訳の 4.7%スペイン: 引用元論文 467 件、この内訳の 3.3%日本: 引用元論文 443 件、この内訳の 3.2%カナダ: 引用元論文 413 件、この内訳の 2.9%オーストラリア: 引用元論文 376 件、この内訳の 2.7%オランダ: 引用元論文 348 件、この内訳の 2.5%スイス: 引用元論文 324 件、この内訳の 2.3%
0%29.5%その他 21.6%

機関

分野

  • Medicine65.8%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Immunology and Microbiology7.3%
  • Engineering2.8%
  • Computer Science0.7%
  • Neuroscience0.6%
  • その他1.9%

トピック

  • Cancer Immunotherapy and Biomarkers14.2%
  • Immunotherapy and Immune Responses6.2%
  • CAR-T cell therapy research4.2%
  • Immune Cell Function and Interaction3.2%
  • Melanoma and MAPK Pathways2.1%
  • Immune cells in cancer2%
  • その他68.1%

共著者

全論文

検索で開く
  1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    著者: Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi - Nature 2014 被引用: 5,302

  2. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

    著者: Leisha A. Emens, Cristina Cruz, Joseph P. Eder, Fadi Braiteh, Cathie T. Chung, Sara M. Tolaney, Irene Kuter, Rita Nanda, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Ehab A. ElGabry, Ching-Wei Chang, Indrani Sarkar, William Grossman, Carol O’Hear, Marcella Fassò, Luciana Molinero, Peter Schmid - JAMA Oncology 2018 被引用: 793

  3. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

    著者: Mary L. Disis, Matthew H. Taylor, Karen Kelly, J. Thaddeus Beck, Michael S. Gordon, Kathleen M. Moore, Manish R. Patel, Jorge Chaves, Haeseong Park, Alain C. Mita, Erika Hamilton, Christina M. Annunziata, H. Grote, Anja von Heydebreck, Jaspreet Singh Grewal, Vikram K. Chand, James L. Gulley - JAMA Oncology 2019 被引用: 427

  4. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

    著者: Ryan B. Corcoran, Thierry André, Chloé E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Gary Middleton, Kei Muro, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O’Dwyer, Y. Humblet, Filip De Vos, A. Scott Jung, Jan C. Brase, Savina Jaeger, Severine Bettinger, Bijoyesh Mookerjee, Fatima Rangwala, Eric Van Cutsem - Cancer Discovery 2018 被引用: 583

  5. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    著者: Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, Michael S. Gordon, Johanna C. Bendell, Do‐Youn Oh, Myung‐Ju Ahn, Elena Garralda, Sandra P. D’Angelo, Jayesh Desai, F. Stephen Hodi, Zev A. Wainberg, Jean‐Pierre Delord, Phillippe A. Cassier, Andrés Cervantes, Marta Gil-Martín, Benjamin Wu, Namrata S. Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond D. Meng, Byoung Chul Cho - JAMA Oncology 2023 被引用: 63

  6. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

    著者: Michael B. Atkins, Michael J. Robertson, Michael S. Gordon, M T Lotze, M DeCoste, J.-B. Dubois, Jerome Ritz, Alan B. Sandler, Howard Edington, Pamela D. Garzone, J W Mier, Christine Canning, Linda A. Battiato, Hideaki Tahara, Matthew L. Sherman - 1997 被引用: 590

  7. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

    著者: Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, Apostolia M. Tsimberidou, Joseph E. Grossman, Michael S. Gordon, Breelyn A. Wilky, Agustin Pimentel, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Ghassan K. Abou‐Alfa, Neil H Segal, Bruno Bockorny, Justin C. Moser, Sunil Sharma, Jaymin Patel, Wei Wu, Dhan Chand, Katherine Rosenthal, Gabriel Mednick, Chloé Delépine, Tyler J. Curiel, Justin Stebbing, Heinz‐Josef Lenz, Steven O’Day, Anthony B. El-Khoueiry - Nature Medicine 2024 被引用: 110

  8. First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

    著者: Neeta Pandit‐Taskar, Michael A. Postow, Matthew D. Hellmann, James J. Harding, Christopher A. Barker, Joseph A. O’Donoghue, Martha Ziolkowska, Shutian Ruan, Serge K. Lyashchenko, Frank Tsai, Michael D. Farwell, Tara C. Mitchell, Ron Korn, William Le, Jason S. Lewis, Wolfgang Weber, Deepak Behera, Ian A. Wilson, Michael S. Gordon, Anna M. Wu, Jedd D. Wolchok - Journal of Nuclear Medicine 2019 被引用: 262

  9. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    著者: Manish R. Patel, John Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Carolyn D. Britten, Luc Dirix, Keun‐Wook Lee, Mathew Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Arnold B. Gelb, Junyuan Xiong, Galit Rosen, James L. Gulley, Andrea B. Apolo - The Lancet Oncology 2017 被引用: 588

  10. CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody

    著者: Michael D. Farwell, Raymond F. Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn, Alessandro Mascioni, William Le, Ian A. Wilson, Michael S. Gordon, Anna M. Wu, Gary A. Ulaner, Jedd D. Wolchok, Michael A. Postow, Neeta Pandit‐Taskar - Journal of Nuclear Medicine 2021 被引用: 124

  11. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    著者: Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith - The Lancet Oncology 2012 被引用: 558

  12. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

    著者: Christophe Massard, Michael S. Gordon, Sunil Sharma, Saeed Rafii, Zev A. Wainberg, Jason J. Luke, Tyler J. Curiel, Gerardo Colón‐Otero, Omid Hamid, Rachel E. Sanborn, Peter H. O’Donnell, Alexandra Drakaki, Winston Tan, John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, Ashok Gupta, Neil H. Segal - Journal of Clinical Oncology 2016 被引用: 845

  13. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

    著者: Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael Millward, Wei Zhang, Ling Gao, Amanda K. Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, KrisAnne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng-Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. Gordon, Ramón V. Tiu, David S. Hong - Molecular Cancer Therapeutics 2019 被引用: 87

  14. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

    著者: Anthony B. El-Khoueiry, Marwan Fakih, Michael S. Gordon, Apostolia M. Tsimberidou, Andrea J. Bullock, Breelyn A. Wilky, Jonathan C. Trent, Kim Margolin, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Bruno Bockorny, Justin C. Moser, Joseph E. Grossman, W.I. Ortuzar Feliu, Katherine Rosenthal, Steven O’Day, Heinz‐Josef Lenz, Benjamin L. Schlechter - Journal of Clinical Oncology 2023 被引用: 55

  15. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

    著者: Antoni Ribas, Alain P. Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael S. Gordon, Leonel F. Hernandez‐Aya, Donald P. Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy K. Mueller, Caroline Robert - Nature Communications 2020 被引用: 88

  16. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

    著者: David F. McDermott, Jeffrey A. Sosman, Mario Sznol, Christophe Massard, Michael S. Gordon, Omid Hamid, John D. Powderly, Jeffrey R. Infante, Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hegde, Gregg Fine, Thomas Powles - Journal of Clinical Oncology 2016 被引用: 558

  17. Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

    著者: Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock, Scot Ebbinghaus, Peter J. O’Dwyer, Michael S. Gordon, William Novotny, Meredith A. Goldwasser, Tanyifor M. Tohnya, Bert L. Lum, Avi Ashkenazi, Adrian M. Jubb, David S. Mendelson - Journal of Clinical Oncology 2010 被引用: 440

  18. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

    著者: Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles - Clinical Cancer Research 2021 被引用: 79

  19. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

    著者: David F. McDermott, Meredith M. Regan, Joseph I. Clark, Lawrence E. Flaherty, Geoffrey R. Weiss, Theodore F. Logan, John M. Kirkwood, Michael S. Gordon, Jeffrey A. Sosman, Marc S. Ernstoff, Christopher Tretter, Walter J. Urba, John W. Smith, Kim Margolin, James W. Mier, Jared Gollob, Janice P. Dutcher, Michael B. Atkins - Journal of Clinical Oncology 2004 被引用: 819

  20. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

    著者: Martin H. Voss, Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David C. Smith, Andrés Cervantes, Igor Puzanov, Роберто Пили, Ding Wang, Shadia I. Jalal, Shubham Pant, Manish R. Patel, Rachel Neuwirth, Aaron Enke, Yaping Shou, Farhad Sedarati, Douglas V. Faller, Howard A. Burris - British Journal of Cancer 2020 被引用: 90

  21. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

    著者: Tae Won Kim, Howard A. Burris, Maria J. de Miguel, Michael J. Pishvaian, Yung‐Jue Bang, Michael S. Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Andrés Cervantes, Laura Q.M. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang‐Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Inêz Padula Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu - Clinical Cancer Research 2022 被引用: 82

  22. Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors

    著者: Juanita Lopez, D. Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schüler, Matthew D. Hellmann, Ani Sarkis Balmanoukian, Luc Dirix, Michael S. Gordon, Ryan J. Sullivan, Brian S. Henick, Charles G. Drake, Kit Man Wong, Patricia LoRusso, Patrick A. Ott, Lawrence Fong, Aglaia Schiza, Jeffery Yachnin, Christian H. Ottensmeier, Fadi Braiteh, Johanna C. Bendell, Rom S. Leidner, George A. Fisher, Guy Jérusalem, Laura Molenaar‐Kuijsten, Marcus Schmidt, Scott A. Laurie, Raid Aljumaily, Achim Rittmeyer, Eelke Gort, Ignacio Melero, Lars Müeller, Rachel Lubong Sabado, Patrick Twomey, Jack Y.J. Huang, M. Yadav, Jingbin Zhang, Felicitas Mueller, Evelyna Derhovanessian, Uğur Şahin, Özlem Türeci, Thomas Powles - Cancer Research 2020 被引用: 59

  23. Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

    著者: David E. Gerber, Jeffrey R. Infante, Michael S. Gordon, Sarah B. Goldberg, Miguel Martín, Enriqueta Felip, Maria Martinez‐García, Joan H. Schiller, David R. Spigel, Julie Cordova, Valerie Westcott, Yulei Wang, David S. Shames, YounJeong Choi, Robert S. Kahn, Randall Dere, Divya Samineni, Jian Xu, Kedan Lin, Katie Wood, Stephanie Royer‐Joo, Vanessa Lemahieu, Eva Schuth, Anjali Vaze, Daniel Maslyar, Eric W. Humke, Howard A. Burris - Clinical Cancer Research 2019 被引用: 53

  24. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

    著者: Toni K. Choueiri, James Larkin, Mototsugu Oya, Fiona Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David F. McDermott, Paul B. Robbins, David D. Chism, Daniel Cho, Michael B. Atkins, Michael S. Gordon, Sumati Gupta, Hirotsugu Uemura, Yoshihiko Tomita, Anna Compagnoni, Camilla Fowst, Alessandra di Pietro, Brian I. Rini - The Lancet Oncology 2018 被引用: 260